Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

In nonlinear pharmacokinetics, saturable pathways cause dose-dependent changes in bioavailability. As drug concentration increases, the absorption pathway becomes saturated, decreasing the absorption rate and resulting in lower bioavailability than expected at higher doses. This saturation limits how much drug reaches systemic circulation.

Protein-bound drugs exhibit longer elimination half-lives and slower elimination rates than free drugs. Only the unbound drug fraction is available for elimination through renal excretion or metabolism, while the protein-bound portion remains in circulation longer. High protein binding reduces the free drug concentration available for glomerular filtration.

Free drug concentration is lower than total drug concentration because most of the drug binds to plasma proteins like albumin. The protein-bound portion remains sequestered in circulation and unavailable for therapeutic action or elimination. Only the unbound fraction represents the pharmacologically active drug available for distribution and clearance.

Pharmacologists use AUC (area under the plasma concentration-time curve from time zero to infinity) to quantify bioavailability. However, AUC can be influenced by saturation-limited absorption in the gastrointestinal tract or concentration-dependent changes affected by drug-metabolizing enzymes, complicating bioavailability estimation for nonlinear drugs.

When absorption pathways saturate at higher doses, the rate of drug absorption decreases despite increased drug concentration. This saturation means the gastrointestinal tract cannot absorb proportionally more drug, resulting in lower bioavailability than predicted by linear kinetics. The saturable pathway becomes a rate-limiting step in drug absorption.

Valproic acid demonstrates nonlinear pharmacokinetics partially due to nonlinear protein binding. Its binding to plasma proteins is not linearly related to its concentration, contributing to dose-dependent bioavailability and variable elimination rates. This nonlinearity exemplifies how protein-drug interactions complicate pharmacokinetic behavior.

Saturable pathways limit absorption and elimination capacity, while protein binding sequesters drug in circulation and reduces free drug availability. Together, these factors cause dose-dependent changes in bioavailability and elimination rates. Understanding parameters affecting nonlinear elimination helps optimize dosing regimens and predict drug behavior across different concentrations.